HC Wainwright & Co. Reiterates Buy on TScan Therapeutics, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on TScan Therapeutics (NASDAQ:TCRX) with a maintained price target of $15.
May 14, 2024 | 11:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TScan Therapeutics receives a reiterated Buy rating from HC Wainwright & Co. with a maintained price target of $15, indicating a positive outlook from the analyst.
Analyst ratings, especially from reputable firms like HC Wainwright & Co., can significantly influence investor sentiment and stock prices in the short term. A reiterated Buy rating and a maintained price target suggest a strong conviction in the company's potential, likely leading to positive investor sentiment and potentially an uptick in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100